Breast Cancer: Phase III study of hormone therapy with or without the study drug (Everolimus)
in high risk hormone receptor positive & HER-2 negative breast cancer (S1207)
This study compares the use of hormones with a study drug (everolimus) to hormones
alone after chemotherapy to see which will keep cancer from returning longer.
Basic Study Information
Purpose:Location: Cancer Center
The purpose of this study is to see whether treatment with everolimus plus hormone
treatment after chemotherapy will increase the time without your cancer returning.
The current standard treatment after chemotherapy is hormone treatment alone. Everolimus
is a drug currently approved for the treatment of patients with advanced or metastatic
kidney cancer or breast cancer. It is considered investigational for non-metastatic
breast cancer patients. In this study you will get hormone treatment with either
everolimus or with placebo (a placebo is a tablet that looks like the active drug,
but has no active drug in it). The combination of hormone-treatment and everolimus
is experimental in patients with breast cancer.
Study Web URL: http://clinicaltrials.gov/ct2/show/NCT01674140?term=S1207&rank=1
Study Reference #: CBRS-13015
Lead Researcher (Principal Investigator)
Lead Researcher: Michelle Shayne, MD
Study Contact InformationStudy Coordinator: Kate Corcoran
Phone: (585) 275-7771
Additional Study Details
Learn More About These Conditions
More information about Breast Cancer
Trial Not Found
The study you are looking for is not active at this time.
Return to Search